Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Causality | 15 | 2024 | 1244 | 3.600 |
Why?
|
Randomized Controlled Trials as Topic | 31 | 2024 | 10218 | 3.010 |
Why?
|
Models, Statistical | 9 | 2024 | 5081 | 1.800 |
Why?
|
Meta-Analysis as Topic | 8 | 2024 | 1381 | 1.640 |
Why?
|
Research Design | 15 | 2024 | 6180 | 1.410 |
Why?
|
Lung Neoplasms | 13 | 2024 | 13385 | 1.050 |
Why?
|
Statistics as Topic | 3 | 2021 | 2359 | 0.910 |
Why?
|
Data Interpretation, Statistical | 8 | 2024 | 2691 | 0.840 |
Why?
|
Models, Theoretical | 3 | 2023 | 3571 | 0.840 |
Why?
|
Propensity Score | 6 | 2020 | 1916 | 0.790 |
Why?
|
Janus Kinase 2 | 4 | 2009 | 559 | 0.790 |
Why?
|
Myocardial Infarction | 9 | 2024 | 11476 | 0.750 |
Why?
|
Citrus sinensis | 1 | 2020 | 15 | 0.720 |
Why?
|
Malus | 1 | 2020 | 50 | 0.690 |
Why?
|
Morals | 1 | 2023 | 289 | 0.690 |
Why?
|
Nutrition Surveys | 3 | 2024 | 1723 | 0.670 |
Why?
|
Epidemiologic Methods | 1 | 2024 | 1336 | 0.650 |
Why?
|
Comparative Effectiveness Research | 4 | 2018 | 709 | 0.630 |
Why?
|
Influenza Vaccines | 2 | 2023 | 767 | 0.630 |
Why?
|
Review Literature as Topic | 3 | 2015 | 348 | 0.610 |
Why?
|
Patient Selection | 4 | 2019 | 4246 | 0.600 |
Why?
|
Influenza, Human | 3 | 2023 | 1521 | 0.580 |
Why?
|
Benchmarking | 3 | 2022 | 1045 | 0.580 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 7 | 2021 | 5321 | 0.570 |
Why?
|
Pharmacoepidemiology | 1 | 2021 | 351 | 0.560 |
Why?
|
Evidence-Based Practice | 2 | 2019 | 493 | 0.560 |
Why?
|
Hypereosinophilic Syndrome | 2 | 2008 | 97 | 0.560 |
Why?
|
Cardiovascular Surgical Procedures | 1 | 2018 | 190 | 0.550 |
Why?
|
Monte Carlo Method | 1 | 2022 | 1256 | 0.550 |
Why?
|
Computer Simulation | 8 | 2024 | 6224 | 0.520 |
Why?
|
Proton Pump Inhibitors | 1 | 2021 | 534 | 0.510 |
Why?
|
Gene Dosage | 2 | 2010 | 1217 | 0.510 |
Why?
|
Humans | 111 | 2024 | 761208 | 0.490 |
Why?
|
Periodicals as Topic | 3 | 2024 | 1463 | 0.480 |
Why?
|
Databases, Bibliographic | 1 | 2015 | 130 | 0.470 |
Why?
|
Early Detection of Cancer | 3 | 2024 | 3198 | 0.470 |
Why?
|
Cathartics | 1 | 2015 | 126 | 0.460 |
Why?
|
Cost Sharing | 1 | 2018 | 409 | 0.460 |
Why?
|
Likelihood Functions | 2 | 2017 | 991 | 0.450 |
Why?
|
Technology Assessment, Biomedical | 1 | 2016 | 306 | 0.450 |
Why?
|
Probability | 5 | 2023 | 2478 | 0.430 |
Why?
|
Medicare | 8 | 2023 | 6773 | 0.430 |
Why?
|
Critical Illness | 2 | 2024 | 2724 | 0.420 |
Why?
|
Medicare Part C | 1 | 2018 | 330 | 0.410 |
Why?
|
Asymptomatic Diseases | 2 | 2014 | 588 | 0.400 |
Why?
|
Antineoplastic Agents | 9 | 2021 | 13632 | 0.390 |
Why?
|
Stroke | 8 | 2016 | 9721 | 0.380 |
Why?
|
Health Services Needs and Demand | 1 | 2019 | 1401 | 0.370 |
Why?
|
Foramen Ovale, Patent | 4 | 2016 | 208 | 0.370 |
Why?
|
Watchful Waiting | 2 | 2012 | 489 | 0.360 |
Why?
|
Genes, p53 | 1 | 2013 | 713 | 0.360 |
Why?
|
Heart Diseases | 1 | 2024 | 2795 | 0.360 |
Why?
|
Coronary Artery Disease | 5 | 2021 | 6505 | 0.360 |
Why?
|
Genes, erbB-2 | 1 | 2011 | 162 | 0.360 |
Why?
|
Aryldialkylphosphatase | 1 | 2010 | 64 | 0.360 |
Why?
|
Rectum | 1 | 2015 | 891 | 0.350 |
Why?
|
Coitus | 1 | 2011 | 134 | 0.350 |
Why?
|
Carotid Stenosis | 2 | 2014 | 859 | 0.350 |
Why?
|
Research Report | 1 | 2013 | 367 | 0.340 |
Why?
|
Hypolipidemic Agents | 1 | 2014 | 609 | 0.340 |
Why?
|
Pneumonia | 1 | 2021 | 2142 | 0.320 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 2 | 2008 | 368 | 0.320 |
Why?
|
Weight-Bearing | 1 | 2011 | 532 | 0.320 |
Why?
|
Polymorphism, Genetic | 5 | 2013 | 4243 | 0.310 |
Why?
|
ras Proteins | 2 | 2011 | 1055 | 0.310 |
Why?
|
ABO Blood-Group System | 1 | 2011 | 381 | 0.310 |
Why?
|
Parity | 1 | 2011 | 929 | 0.310 |
Why?
|
Abortion, Habitual | 1 | 2008 | 61 | 0.310 |
Why?
|
Cardiac Surgical Procedures | 2 | 2021 | 3627 | 0.300 |
Why?
|
Glutathione Transferase | 1 | 2010 | 564 | 0.300 |
Why?
|
Sample Size | 2 | 2021 | 843 | 0.300 |
Why?
|
Colorectal Neoplasms | 5 | 2013 | 6919 | 0.300 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2018 | 1186 | 0.300 |
Why?
|
Diagnostic Tests, Routine | 1 | 2013 | 788 | 0.290 |
Why?
|
Mutation | 8 | 2011 | 30002 | 0.280 |
Why?
|
mRNA Cleavage and Polyadenylation Factors | 1 | 2007 | 105 | 0.280 |
Why?
|
Colon | 1 | 2015 | 1791 | 0.280 |
Why?
|
Thrombocythemia, Essential | 1 | 2008 | 113 | 0.280 |
Why?
|
Mammography | 1 | 2018 | 2430 | 0.280 |
Why?
|
SEER Program | 3 | 2021 | 1453 | 0.280 |
Why?
|
Death, Sudden, Cardiac | 2 | 2014 | 1560 | 0.270 |
Why?
|
Polycythemia Vera | 1 | 2008 | 161 | 0.270 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2007 | 58 | 0.270 |
Why?
|
Patient-Centered Care | 1 | 2016 | 1427 | 0.270 |
Why?
|
Preoperative Care | 1 | 2015 | 2241 | 0.260 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2006 | 106 | 0.260 |
Why?
|
Genetic Predisposition to Disease | 4 | 2011 | 17897 | 0.260 |
Why?
|
Databases, Factual | 4 | 2018 | 7966 | 0.260 |
Why?
|
Sepsis | 1 | 2020 | 2585 | 0.260 |
Why?
|
Epidemiologic Studies | 2 | 2024 | 677 | 0.250 |
Why?
|
Musculoskeletal Diseases | 1 | 2011 | 598 | 0.250 |
Why?
|
Atrial Fibrillation | 2 | 2022 | 5114 | 0.250 |
Why?
|
Positron-Emission Tomography | 4 | 2014 | 6585 | 0.240 |
Why?
|
Organoplatinum Compounds | 1 | 2006 | 407 | 0.240 |
Why?
|
Fibrinolytic Agents | 1 | 2014 | 2075 | 0.240 |
Why?
|
Thoracic Wall | 1 | 2007 | 202 | 0.240 |
Why?
|
Thiazolidinediones | 1 | 2008 | 460 | 0.240 |
Why?
|
Nose Neoplasms | 1 | 2007 | 249 | 0.240 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 8003 | 0.240 |
Why?
|
Antibodies, Monoclonal | 4 | 2011 | 9187 | 0.230 |
Why?
|
Thoracic Neoplasms | 1 | 2007 | 268 | 0.230 |
Why?
|
Decision Making | 2 | 2018 | 3931 | 0.230 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2020 | 4021 | 0.230 |
Why?
|
Treatment Outcome | 14 | 2024 | 64681 | 0.220 |
Why?
|
Protein Kinase Inhibitors | 5 | 2010 | 5662 | 0.220 |
Why?
|
Biomedical Research | 3 | 2019 | 3434 | 0.210 |
Why?
|
Point Mutation | 1 | 2008 | 1593 | 0.210 |
Why?
|
Electronic Health Records | 2 | 2024 | 4822 | 0.210 |
Why?
|
Acute Coronary Syndrome | 2 | 2012 | 2194 | 0.200 |
Why?
|
Confidence Intervals | 4 | 2011 | 2928 | 0.200 |
Why?
|
Risk Factors | 13 | 2021 | 74239 | 0.200 |
Why?
|
Proto-Oncogene Proteins | 2 | 2011 | 4513 | 0.190 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2024 | 287 | 0.190 |
Why?
|
Evidence-Based Medicine | 5 | 2018 | 3691 | 0.190 |
Why?
|
Biometry | 1 | 2024 | 563 | 0.190 |
Why?
|
Intestinal Perforation | 1 | 2023 | 249 | 0.190 |
Why?
|
Sensitivity and Specificity | 5 | 2024 | 14675 | 0.180 |
Why?
|
Oximetry | 1 | 2024 | 459 | 0.180 |
Why?
|
Survival Rate | 7 | 2021 | 12728 | 0.180 |
Why?
|
Epidemiologic Research Design | 1 | 2024 | 368 | 0.180 |
Why?
|
Neoplasm Staging | 5 | 2021 | 11119 | 0.170 |
Why?
|
North America | 1 | 2024 | 1284 | 0.170 |
Why?
|
Myelodysplastic Syndromes | 1 | 2010 | 1393 | 0.170 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2010 | 2915 | 0.170 |
Why?
|
Policy | 1 | 2023 | 506 | 0.170 |
Why?
|
Coronary Thrombosis | 1 | 2022 | 440 | 0.170 |
Why?
|
Coronary Artery Bypass | 2 | 2019 | 2193 | 0.170 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2007 | 1605 | 0.160 |
Why?
|
Enterocolitis, Necrotizing | 1 | 2023 | 326 | 0.160 |
Why?
|
Uncertainty | 1 | 2024 | 752 | 0.160 |
Why?
|
United States | 12 | 2023 | 72339 | 0.160 |
Why?
|
Data Mining | 2 | 2014 | 554 | 0.160 |
Why?
|
Eligibility Determination | 1 | 2022 | 420 | 0.160 |
Why?
|
Regression Analysis | 2 | 2023 | 6345 | 0.160 |
Why?
|
Case-Control Studies | 5 | 2021 | 22174 | 0.160 |
Why?
|
Pyridones | 1 | 2024 | 809 | 0.160 |
Why?
|
Nursing Homes | 2 | 2023 | 1083 | 0.150 |
Why?
|
Odds Ratio | 4 | 2011 | 9652 | 0.150 |
Why?
|
Infant, Newborn, Diseases | 1 | 2023 | 589 | 0.150 |
Why?
|
Aged | 16 | 2023 | 169288 | 0.150 |
Why?
|
Piperazines | 2 | 2024 | 2522 | 0.140 |
Why?
|
Genetic Association Studies | 3 | 2011 | 2731 | 0.140 |
Why?
|
Infant, Premature, Diseases | 1 | 2023 | 710 | 0.140 |
Why?
|
Brain Ischemia | 1 | 2010 | 3032 | 0.140 |
Why?
|
Bayes Theorem | 2 | 2017 | 2329 | 0.140 |
Why?
|
PubMed | 2 | 2015 | 129 | 0.140 |
Why?
|
Live Birth | 1 | 2020 | 511 | 0.140 |
Why?
|
Cluster Analysis | 1 | 2024 | 2706 | 0.140 |
Why?
|
Female | 30 | 2023 | 392544 | 0.140 |
Why?
|
Validation Studies as Topic | 1 | 2017 | 162 | 0.140 |
Why?
|
Hydroxyurea | 2 | 2008 | 284 | 0.130 |
Why?
|
Shock, Septic | 1 | 2023 | 769 | 0.130 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2014 | 2509 | 0.130 |
Why?
|
Therapeutics | 1 | 2016 | 113 | 0.130 |
Why?
|
Delivery of Health Care | 1 | 2014 | 5333 | 0.130 |
Why?
|
Authorship | 1 | 2019 | 284 | 0.130 |
Why?
|
Fever of Unknown Origin | 1 | 2016 | 94 | 0.130 |
Why?
|
Fertility | 1 | 2020 | 768 | 0.130 |
Why?
|
Anticoagulants | 4 | 2021 | 4795 | 0.130 |
Why?
|
Critical Care | 2 | 2020 | 2696 | 0.120 |
Why?
|
Access to Information | 1 | 2018 | 316 | 0.120 |
Why?
|
Hydrocortisone | 1 | 2023 | 1818 | 0.120 |
Why?
|
Hypoglycemic Agents | 1 | 2008 | 3089 | 0.120 |
Why?
|
Septal Occluder Device | 1 | 2016 | 125 | 0.120 |
Why?
|
Cardiovascular Agents | 1 | 2021 | 842 | 0.120 |
Why?
|
Enema | 1 | 2015 | 141 | 0.120 |
Why?
|
Breast Neoplasms | 3 | 2013 | 20982 | 0.120 |
Why?
|
Calibration | 1 | 2017 | 819 | 0.110 |
Why?
|
Exercise | 1 | 2011 | 5874 | 0.110 |
Why?
|
Middle Aged | 18 | 2024 | 220853 | 0.110 |
Why?
|
Survival Analysis | 2 | 2021 | 10088 | 0.110 |
Why?
|
Heparin | 1 | 2021 | 1632 | 0.110 |
Why?
|
Reproducibility of Results | 5 | 2016 | 20119 | 0.110 |
Why?
|
Random Allocation | 1 | 2018 | 2393 | 0.110 |
Why?
|
Human papillomavirus 18 | 1 | 2014 | 125 | 0.110 |
Why?
|
Colonic Neoplasms | 2 | 2020 | 2527 | 0.110 |
Why?
|
Law Enforcement | 1 | 2014 | 112 | 0.110 |
Why?
|
Genes, myc | 1 | 2014 | 390 | 0.110 |
Why?
|
Nuclear Medicine | 1 | 2016 | 257 | 0.100 |
Why?
|
Postoperative Complications | 1 | 2015 | 15637 | 0.100 |
Why?
|
Prognosis | 8 | 2020 | 29687 | 0.100 |
Why?
|
Prenatal Care | 1 | 2020 | 1141 | 0.100 |
Why?
|
Police | 1 | 2014 | 157 | 0.100 |
Why?
|
Heart-Assist Devices | 1 | 2023 | 1288 | 0.100 |
Why?
|
Oxygen | 1 | 2024 | 4227 | 0.100 |
Why?
|
Human papillomavirus 16 | 1 | 2014 | 267 | 0.100 |
Why?
|
Prostatic Neoplasms | 2 | 2012 | 11101 | 0.100 |
Why?
|
Endarterectomy, Carotid | 2 | 2014 | 554 | 0.100 |
Why?
|
Digital Rectal Examination | 1 | 2012 | 41 | 0.100 |
Why?
|
Drug-Eluting Stents | 1 | 2018 | 681 | 0.100 |
Why?
|
Angioplasty | 1 | 2014 | 356 | 0.100 |
Why?
|
HIV Infections | 3 | 2024 | 17347 | 0.100 |
Why?
|
Genome-Wide Association Study | 1 | 2011 | 12676 | 0.100 |
Why?
|
Proline | 1 | 2013 | 455 | 0.090 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 15920 | 0.090 |
Why?
|
Disease-Free Survival | 3 | 2014 | 6819 | 0.090 |
Why?
|
Male | 21 | 2023 | 360693 | 0.090 |
Why?
|
Bibliometrics | 1 | 2015 | 352 | 0.090 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2018 | 1724 | 0.090 |
Why?
|
Loss of Heterozygosity | 1 | 2013 | 662 | 0.090 |
Why?
|
Algorithms | 2 | 2022 | 14025 | 0.090 |
Why?
|
Alleles | 2 | 2013 | 6857 | 0.090 |
Why?
|
Lymphoma | 2 | 2010 | 1898 | 0.090 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 382 | 0.090 |
Why?
|
Classification | 1 | 2011 | 128 | 0.090 |
Why?
|
Follow-Up Studies | 4 | 2021 | 39126 | 0.090 |
Why?
|
Referral and Consultation | 1 | 2023 | 3608 | 0.090 |
Why?
|
Neoplasm Metastasis | 1 | 2021 | 4909 | 0.090 |
Why?
|
Radiography, Thoracic | 1 | 2017 | 1302 | 0.090 |
Why?
|
Veterans | 1 | 2024 | 2654 | 0.090 |
Why?
|
Skull | 1 | 2014 | 818 | 0.080 |
Why?
|
Logistic Models | 2 | 2022 | 13249 | 0.080 |
Why?
|
Chronic Disease | 2 | 2019 | 9319 | 0.080 |
Why?
|
Cardiovascular Diseases | 2 | 2022 | 15520 | 0.080 |
Why?
|
Administration, Oral | 2 | 2015 | 4015 | 0.080 |
Why?
|
Risk | 2 | 2011 | 9616 | 0.080 |
Why?
|
Combined Modality Therapy | 1 | 2021 | 8519 | 0.080 |
Why?
|
Telomerase | 1 | 2014 | 741 | 0.080 |
Why?
|
Aorta | 1 | 2017 | 2040 | 0.080 |
Why?
|
Sex Factors | 2 | 2021 | 10553 | 0.080 |
Why?
|
Peptide Fragments | 1 | 2021 | 5103 | 0.080 |
Why?
|
Registries | 2 | 2022 | 8247 | 0.080 |
Why?
|
Health Expenditures | 1 | 2021 | 2362 | 0.080 |
Why?
|
Adult | 13 | 2024 | 221119 | 0.080 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26071 | 0.080 |
Why?
|
Glioma | 2 | 2013 | 3452 | 0.070 |
Why?
|
Sjogren's Syndrome | 1 | 2009 | 238 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 2 | 2024 | 20588 | 0.070 |
Why?
|
Age Factors | 3 | 2021 | 18384 | 0.070 |
Why?
|
Genetic Heterogeneity | 1 | 2010 | 734 | 0.070 |
Why?
|
Genetic Markers | 2 | 2010 | 2599 | 0.070 |
Why?
|
Cytogenetic Analysis | 1 | 2007 | 270 | 0.070 |
Why?
|
Drug Therapy, Combination | 3 | 2023 | 6304 | 0.070 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2011 | 424 | 0.070 |
Why?
|
Aged, 80 and over | 3 | 2021 | 58952 | 0.070 |
Why?
|
Quinazolines | 2 | 2010 | 1371 | 0.070 |
Why?
|
Morbidity | 1 | 2012 | 1751 | 0.070 |
Why?
|
Occupational Diseases | 1 | 2014 | 1490 | 0.070 |
Why?
|
Genotype | 2 | 2011 | 12985 | 0.070 |
Why?
|
Disease Progression | 3 | 2012 | 13511 | 0.070 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2011 | 1746 | 0.060 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2015 | 2746 | 0.060 |
Why?
|
Genes, ras | 1 | 2008 | 654 | 0.060 |
Why?
|
Stents | 2 | 2014 | 3177 | 0.060 |
Why?
|
Hematologic Diseases | 1 | 2009 | 496 | 0.060 |
Why?
|
Prostate-Specific Antigen | 2 | 2012 | 2465 | 0.060 |
Why?
|
Risk Assessment | 4 | 2016 | 24021 | 0.060 |
Why?
|
Immunoenzyme Techniques | 1 | 2008 | 1703 | 0.060 |
Why?
|
Cross-Over Studies | 1 | 2011 | 2082 | 0.060 |
Why?
|
Nasal Cavity | 1 | 2007 | 304 | 0.060 |
Why?
|
Treatment Failure | 1 | 2011 | 2643 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2010 | 5300 | 0.060 |
Why?
|
RNA | 1 | 2014 | 2709 | 0.060 |
Why?
|
Neoplasms | 1 | 2013 | 22140 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 1 | 2011 | 36415 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7804 | 0.060 |
Why?
|
Endometrial Neoplasms | 1 | 2013 | 1366 | 0.060 |
Why?
|
Gene Amplification | 1 | 2008 | 1084 | 0.060 |
Why?
|
Fludrocortisone | 1 | 2023 | 24 | 0.050 |
Why?
|
Biopsy | 2 | 2013 | 6781 | 0.050 |
Why?
|
Low Back Pain | 1 | 2011 | 983 | 0.050 |
Why?
|
Knee Joint | 1 | 2011 | 1678 | 0.050 |
Why?
|
Prednisone | 1 | 2007 | 1565 | 0.050 |
Why?
|
Adenocarcinoma | 1 | 2020 | 6341 | 0.050 |
Why?
|
Consensus | 2 | 2023 | 3134 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2020 | 5366 | 0.050 |
Why?
|
Lumbar Vertebrae | 1 | 2011 | 1876 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2016 | 3534 | 0.050 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2014 | 2019 | 0.050 |
Why?
|
Methotrexate | 1 | 2008 | 1718 | 0.050 |
Why?
|
Benzamides | 1 | 2007 | 1371 | 0.050 |
Why?
|
Translocation, Genetic | 1 | 2007 | 1391 | 0.050 |
Why?
|
Oxazines | 1 | 2024 | 349 | 0.050 |
Why?
|
Stem Cell Transplantation | 1 | 2010 | 1600 | 0.050 |
Why?
|
Infusions, Intravenous | 1 | 2006 | 2217 | 0.050 |
Why?
|
Brain Neoplasms | 2 | 2013 | 9025 | 0.050 |
Why?
|
Rehabilitation Centers | 1 | 2023 | 246 | 0.050 |
Why?
|
Motor Activity | 1 | 2011 | 2712 | 0.050 |
Why?
|
Cell Division | 1 | 2008 | 4451 | 0.050 |
Why?
|
Laparotomy | 1 | 2023 | 456 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 4567 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2015 | 3976 | 0.040 |
Why?
|
Hirudins | 1 | 2021 | 179 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 3245 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2008 | 3512 | 0.040 |
Why?
|
Quality Improvement | 1 | 2014 | 3808 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2010 | 2223 | 0.040 |
Why?
|
Computational Biology | 1 | 2011 | 3499 | 0.040 |
Why?
|
Data Collection | 2 | 2022 | 3320 | 0.040 |
Why?
|
Research Personnel | 1 | 2023 | 588 | 0.040 |
Why?
|
Area Under Curve | 1 | 2022 | 1636 | 0.040 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2011 | 1874 | 0.040 |
Why?
|
Recurrence | 1 | 2011 | 8457 | 0.040 |
Why?
|
Antithrombins | 1 | 2021 | 294 | 0.040 |
Why?
|
Sweden | 1 | 2021 | 1379 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 1 | 2012 | 3200 | 0.040 |
Why?
|
American Heart Association | 1 | 2022 | 1043 | 0.040 |
Why?
|
Shock, Cardiogenic | 1 | 2023 | 709 | 0.040 |
Why?
|
Receptor, erbB-2 | 1 | 2008 | 2553 | 0.040 |
Why?
|
Electronic Mail | 1 | 2019 | 213 | 0.040 |
Why?
|
Thrombectomy | 1 | 2022 | 703 | 0.040 |
Why?
|
Flow Cytometry | 1 | 2008 | 5871 | 0.040 |
Why?
|
Aftercare | 1 | 2023 | 913 | 0.040 |
Why?
|
Cohort Studies | 3 | 2023 | 41496 | 0.040 |
Why?
|
Costs and Cost Analysis | 1 | 2022 | 1664 | 0.030 |
Why?
|
Adjuvants, Immunologic | 1 | 2021 | 988 | 0.030 |
Why?
|
Ovarian Neoplasms | 1 | 2013 | 4872 | 0.030 |
Why?
|
Coronary Disease | 1 | 2010 | 5921 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2023 | 80674 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2014 | 5842 | 0.030 |
Why?
|
Gene Expression | 1 | 2008 | 7571 | 0.030 |
Why?
|
Phenotype | 2 | 2010 | 16575 | 0.030 |
Why?
|
Hematopoietic Stem Cells | 1 | 2008 | 3388 | 0.030 |
Why?
|
Telephone | 1 | 2019 | 624 | 0.030 |
Why?
|
Deoxycytidine | 1 | 2020 | 878 | 0.030 |
Why?
|
Young Adult | 3 | 2012 | 59221 | 0.030 |
Why?
|
Pyrimidines | 1 | 2007 | 3027 | 0.030 |
Why?
|
Fluorouracil | 1 | 2020 | 1642 | 0.030 |
Why?
|
ROC Curve | 1 | 2022 | 3584 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2012 | 9278 | 0.030 |
Why?
|
Decision Making, Organizational | 1 | 2014 | 136 | 0.030 |
Why?
|
Canada | 1 | 2019 | 2125 | 0.030 |
Why?
|
Anti-Inflammatory Agents | 1 | 2023 | 1812 | 0.030 |
Why?
|
Pregnancy | 2 | 2020 | 29893 | 0.030 |
Why?
|
Arthritis, Rheumatoid | 1 | 2008 | 3753 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2013 | 2024 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 1 | 2023 | 6486 | 0.030 |
Why?
|
Disease Outbreaks | 1 | 2021 | 1747 | 0.020 |
Why?
|
Radiopharmaceuticals | 2 | 2013 | 2683 | 0.020 |
Why?
|
Vaccination | 1 | 2024 | 3369 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2023 | 26199 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2022 | 5250 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2021 | 6504 | 0.020 |
Why?
|
Apolipoprotein E2 | 1 | 2011 | 135 | 0.020 |
Why?
|
Methionine | 1 | 2013 | 570 | 0.020 |
Why?
|
Prosthesis Failure | 1 | 2016 | 1204 | 0.020 |
Why?
|
Incidence | 2 | 2021 | 21365 | 0.020 |
Why?
|
Patient Discharge | 1 | 2023 | 3441 | 0.020 |
Why?
|
Adolescent | 4 | 2024 | 88298 | 0.020 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2011 | 328 | 0.020 |
Why?
|
Heart | 1 | 2023 | 4431 | 0.020 |
Why?
|
Hospitals | 1 | 2023 | 3881 | 0.020 |
Why?
|
Hypergammaglobulinemia | 1 | 2009 | 71 | 0.020 |
Why?
|
Patient Readmission | 1 | 2023 | 3265 | 0.020 |
Why?
|
Greece | 1 | 2009 | 340 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2016 | 12474 | 0.020 |
Why?
|
Infant | 2 | 2023 | 36169 | 0.020 |
Why?
|
Workload | 1 | 2013 | 845 | 0.020 |
Why?
|
Apolipoprotein E4 | 1 | 2011 | 709 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 11733 | 0.020 |
Why?
|
Ischemic Attack, Transient | 1 | 2011 | 874 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2011 | 1472 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2010 | 2112 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2022 | 5425 | 0.010 |
Why?
|
Cerebrovascular Disorders | 1 | 2011 | 1474 | 0.010 |
Why?
|
Information Dissemination | 1 | 2013 | 1129 | 0.010 |
Why?
|
Pattern Recognition, Automated | 1 | 2011 | 993 | 0.010 |
Why?
|
Child | 3 | 2023 | 80152 | 0.010 |
Why?
|
Prevalence | 2 | 2012 | 15721 | 0.010 |
Why?
|
Forecasting | 1 | 2013 | 2928 | 0.010 |
Why?
|
Salvage Therapy | 1 | 2010 | 1264 | 0.010 |
Why?
|
Heart Failure | 1 | 2008 | 11701 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8663 | 0.010 |
Why?
|
Prospective Studies | 1 | 2007 | 54435 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2010 | 4107 | 0.010 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2009 | 1372 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2015 | 7046 | 0.010 |
Why?
|
Neurosurgical Procedures | 1 | 2011 | 2067 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2011 | 4340 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2014 | 4487 | 0.010 |
Why?
|
Software | 1 | 2013 | 4431 | 0.010 |
Why?
|
Antirheumatic Agents | 1 | 2008 | 1369 | 0.010 |
Why?
|
Acute Disease | 1 | 2009 | 7226 | 0.010 |
Why?
|
Proteomics | 1 | 2011 | 3840 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2008 | 10756 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2009 | 12052 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2011 | 14610 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2010 | 15308 | 0.010 |
Why?
|
Child, Preschool | 1 | 2014 | 42224 | 0.010 |
Why?
|
Time Factors | 1 | 2008 | 39957 | 0.000 |
Why?
|